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This paper addresses the possibility of mathematically partition and process urine 1H-NMR spectra to enhance the eﬃciency of
the subsequent multivariate data analysis in the context of metabolic proﬁling of a toxicity study. We show that by processing the
NMR data with the peak alignment using reduced set mapping (PARS) algorithm and the use of sparse representation of the data
results in the information contained in the original NMR data being preserved with retained resolution but free of the problem of
peak shifts. We can now describe a method for diﬀerential expression analysis of NMR spectra by using prior knowledge, i.e., the
onset of dosing, a partitioning not possible to achieve using raw or bucketed data. In addition we also outline a scheme for soft
removal of ‘‘biological noise’’ from the aligned data: exhaustive bio-noise subtraction (EBS). The result is a straightforward
protocol for detection of peaks that appear as a consequence of the drug response. In other words, it is possible to elucidate peak
origin, either from endogenous substances or from the administered drug/biomarkers. The partition of data originating from the
normally regulating metabolome can, furthermore, be analyzed free of the superimposed biological noise. The proposed protocol
results in enhanced interpretability of the processed data, i.e., a more reﬁned metabolic trace, simpliﬁcation of detection of
consistent biomarkers, and a simpliﬁed search for metabolic end products of the administered drug.
KEY WORDS: urine; bioﬂuid; 1H-NMR; peak alignment; multivariate; metabolic proﬁling; hepatic steatosis.
1. Introduction
1H-NMR data of complex bioﬂuid samples exhibit
artifacts, ‘‘physicochemical diﬀerences,’’ making inter-
pretation of the multivariate models of the data some-
what problematic. The major data artifacts can be
summarized: peak shifts, peak shape distortions (shim
problems), and unsuccessful phasing. Other evident
problems encountered when analyzing bioﬂuid NMR
data are, for example, the inherent bio-variability rela-
ted to the metabolome of the model system under study
such as diurnal variability, individual diﬀerences, dif-
ferent hormone levels, and (if applicable), confounded
variances related to the event of dosing such as stress,
starvation, weight loss, alteration of the gut ﬂora, etc.
Finally, there are (variable) co-correlation and large
diﬀerences in variance magnitude expressed by the peaks
in the data, all of which make the search for small
variance contributions a diﬃcult task.
1.1. Physicochemical diﬀerences
Diﬀerent methods have been proposed to remedy the
physicochemical diﬀerences, typically by preprocessing
the acquired NMR data. The most commonly applied
method today is the integration of large segments of the
NMR data into ‘‘buckets’’ (Spraul et al., 1994; Holmes
et al., 1998) with the aim of collecting unaligned peaks
into single buckets. The drawback of the bucketing
procedure is the destruction of the high-resolution
information by extensive down-sampling of the spectra.
As an example: a modest peak detection algorithm
indicates that there are approximately 800–1200 peaks
present in a 600 MHz NMR spectrum of urine from a
healthy rat. When bucketing the spectrum into 250
buckets there will, by mathematical necessity, be on
average 3–5 peaks (possibly of diﬀerent origin) per
bucket. It is unlikely that these peaks express the same
variance pattern, so the resulting integral value will
express something diﬀerent than the true variance con-
tributions. The 3–5 peak number is crude and optimistic
since the real situation is much worse – the spectral
peaks are not evenly distributed in the NMR spectrum
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and the used peak picking algorithm does not detect all
the minute peaks present. However, the alignment/res-
olution problem is solved using peak alignment.
Also, the positions of interesting peaks, i.e., peaks
occurring as a result of the administered drug or as a
consequence of a toxic lesion (potential biomarkers), are
usually unknown, making the bucketing procedure
integrate peaks of diﬀerent origin and hence leading to a
potentially misleading data analysis result when these
buckets are later to be modeled for interesting variance
contributions by multivariate methods, i.e., variance
mapping methods, principal component analysis (PCA)
(Pearson, 1901; Hotelling, 1933; Jackson, 1991) being
the most widely used unsupervised multivariate method.
PCA decomposes data with descending magnitude of
variance as the criterion for mapping the interesting
variance patterns of the variables (relative NMR fre-
quency [ppm]). If peaks with varying variances share the
same bucket, the peak with the largest variance will
dominate the variance pattern, thereby eﬀectively
‘‘drowning’’ smaller peaks. Even worse – spurious
variances can accumulate and/or co-correlated and
interesting peak variances can be cancelled or blurred.
On the other hand, if the spectra were to be modeled in
their raw form, the largest expressed variance patterns
(loadings) will consist of ‘‘shift patterns’’ (Brown and
Stoyanova, 1996; Siuda et al., 1998) expressing the shifts
of the largest shifting peaks. Furthermore, added to the
shift patterns is information of the inter sample peak
shape diﬀerences. These shift and shape patterns are of
minor interest from a toxicological/metabolic point of
view even though it can be stated that the peak shifts
express other variables like pH or other ion concentra-
tion of the sample (Cloarec et al., 2005).
From a multivariate modeling point of view, there is
nothing to be gained from confounding the plethora of
NMR peaks reﬂecting the complex metabolome with the
typically univariate parameters mentioned above. If
these univariate parameters are of interest, they are best
appended to the data in the same way as one would
append any other object/sample related study data in
the modeling step. The modeling of shift/shape patterns
will also deplete the data of useful variance since all
variances having a directional component (not orthog-
onal), with the principal components expressing shift
vectors will also, to some extent, be included in the same
latent variable, eﬀectively reducing the overall variance
in the data regardless of origin. The overall result of
using the ‘‘bucket’’ approach or using raw data is that
the prospect of modeling or ﬁnding small interesting
peaks is decreased.
1.2. Biological noise
The other major source of unwanted variance has its
origin in normal physiological variation or ‘‘biological
noise.’’ It is known that that the largest variances of the
spectral peaks have their origin in perfectly normal
compositional variation of endogenous metabolites that
by nature exhibit a large natural time variation. The
sources of this normal variation can be traced to (in this
study) inter-animal variation (Bollard et al., 2001) and
the diurnal cycle (Bollard et al., 2001) of the rat.
There have been quite a number of attempts to
remedy the ‘‘biological noise’’ and variance magnitude
diﬀerence problem, e.g., by imposing diﬀerent data
scaling or transformations such as autoscaling, VAST
scaling (Keun et al., 2003), Pareto scaling (Wold et al.,
1993), OSC-pretreatment (Andersson et al., 1998),
optimized scaling (Karstang and Manne, 1992), etc. The
scaling transformations have the aim of transforming
the variable variances to have (more) equal numerical
magnitudes from a variance-modeling point of view.
The desired result is that small variances appear in
earlier principal components as they become more pro-
nounced, hopefully making these variables easier to
detect. The use of diﬀerent scaling schemes is the subject
of ongoing discussion. The implementation of the dif-
ferent scaling methods and the possible combination of
methods is more or less ad lib, making the results from
diﬀerent studies diﬃcult to compare, even though
‘‘backscaling’’ can be performed (Cloarec et al., 2005).
Furthermore, scaling schemes such as VAST, OSC, and
optimized scaling incorporate prior knowledge (super-
vised modeling) in the scaling operation, making the
quality and validity of the resulting models harder to
judge, especially if the following model choice is also
supervised with the same classiﬁers (Y), since the scaled
variables are superimposed with class information from
the scaling step. The scaling steps based on estimation of
variance, e.g., auto- and Pareto scaling, are also founded
on the (weak) assumption that the data have an
approximately symmetric distribution – a condition not
satisﬁed by the data from a toxicological study.
In this paper we compare three diﬀerent approaches
to process NMR data prior to multivariate data analy-
sis, namely peak alignment using the PARS algorithm
(Torgrip et al., 2003; A˚berg et al., 2005; Forshed et al.,
2005), the traditional ‘‘bucketing’’ scheme and down-
sampled raw data. A method is proposed to diﬀerentiate
interesting sets of metabolites (variables) with respect to
causality without loosing the resolution of the NMR data
by means of diﬀerential expression analysis of the
aligned data, a method that can be regarded as unsu-
pervised. Furthermore, a method for removal of ‘‘bio-
logical noise’’ by projection/subtraction is outlined. The
resulting protocol is a straightforward data partitioning
(and projection) where the resulting partitioned datasets
are analyzed with an unsupervised method (PCA). The
data used to illustrate the processing protocol are
600 MHz 1H-NMR spectra of rat urine from a time-
series study of the metabolic impact of DL-ethionine, a
model substance used for induction of hepatic steatosis
(fatty liver).
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2. Experimental
2.1. Animals and treatments
Thirty-ﬁve male rats, 5 per group (Han Wistar, sub-
strain BrlHan:WIST@Mo, approximately 2 months of
age at study onset, weight range 220–320 g) were used in
the study. Animals were multiple-housed (2 or 3 per
cage) during an acclimatization period in the animal
house (10 days). During the course of the study, 5 ani-
mals/group were housed in individual metabolism cages
to allow for the continuous collection of urine. Animals
from group 1–3 were dosed by oral gavage in 10 mL/kg
PBS with DL-ethionine (DL-2-amino-4-[ethylthio]butyric
acid) for 7 days beginning on day 1 and necropsied on
day 8, when tissues were taken for pathology. Animals
in group 4 were dosed on day 1 and urine was collected
until necropsy on day 8. For the animals in groups 1–4,
environmental enrichment was provided (crawl balls).
Animals in groups 5–7 received a single dose of ethio-
nine on day 1 and were necropsied 24 h after dosing.
For details of the animal treatment, see Table 1. The
study was performed according to national animal-
study regulations.
2.2. Sample collection
Urine samples were collected on ice in 1% (1 mL, w/v)
sodium azide prior to dosing (days )5 and )2, one
sample/day) and on days 1–7 (0–7 h and 8–24 h, two
samples/day [AM/PM]). Urine pH was recorded and the
samples were centrifuged at 500 g for 10 min and the
supernatant was then retained at )80 C until analysis
with NMR spectroscopy. This scheme resulted in 16
samples/animal for groups 1–4, and 4 samples/animal
for groups 5–7.
Although we have not used all the information
gathered in this paper, we report the full sampling for
completeness. Blood samples for hematology and blood
chemistry were taken from the orbital plexus prior to
necropsy. Selected organs for histopathology, including
liver, kidney, heart, adrenal glands, lungs, pancreas,
spleen, stomach, thymus, and testes, were retained at
necropsy. Tissue samples were ﬁxed in 10% (w/v)
phosphate-buﬀered formalin and embedded in paraﬃn
wax. Sections were cut and stained with hematoxylin
and eosin for light microscopy. Samples from the liver
were also freeze-sectioned and stained for fat with Oil
Red-O.
2.3. 1H-NMR-spectroscopic analysis of urine samples
Aliquots of urine (400 lL) were mixed with 200 lL of
0.2 M phosphate buﬀer (Na2HPO4/NaH2PO4,
pH=7.4). TSP (3-trimethylsilyl-1-[2,2,3,3,)2H4] propi-
onate, internal standard) was prepared in deuterium
oxide (D2O) and added to a ﬁnal concentration of
0.09 mg/ml.
NMR data were acquired on a Bruker DRX-600
spectrometer operating at 600.23 MHz for 1H observa-
tion (Bruker Analytische Messtechnik GmbH, Rhein-
stetten, Germany). The 4 mm FISEI 1H–13C Z-GRD
probe was employed for sample analysis. Spectra were
acquired using a standard Bruker NOESY presaturation
pulse program (relaxation delay–90–t1–90–tm–90–
acquire-FID), where tm was set to 100 ms. The residual
water resonances were suppressed, by presaturation
during the relaxation and mixing time (tm). Spectral
acquisition parameters used were: 64 free induction
decays (FIDs) were collected (64 k data), 12019 Hz
spectral width, 2.73 s acquisition time, 4.83 s total pulse
recycle delay, at 300 K. The FIDs were zero ﬁlled to
64 k and multiplied by an exponential weighting func-
tion equivalent to a line broadening of 0.3 Hz prior to
Fourier transformation. The study protocol resulted in
336 (of 340 possible) good-quality NMR spectra for
further analysis.
3. Theory
3.1. Syntax and deﬁnitions
In this paper matrices are expressed as bold capitals,
sets and operators as italic capitals, and scalars as italic
letters. The term ‘‘PCN’’ is used for PCA dimensional-
ity, where N stands for the actual dimension of the
model in question. The term ‘‘score(s)’’ is the projections
of the data in question on the principal component
‘‘loading’’ (N). Throughout this paper the term ‘‘vari-
able’’ refers to the ppm annotated NMR spectral
intensities. The term ‘‘bucketed variable’’ refers to the
center value (ppm) of integrated regions of measured
NMR spectral intensities.
We deﬁne for a data set of size (R[ows],C[olumns]) a
set descriptor, SD, as:
SD ¼ fR;Cg
where R is a ﬁnite set of objects (rat urine spectrum)
R={r1, r2, ..., rm}, and C is a ﬁnite set of variables
(relative NMR frequency [ppm]), C={c1,c2,...,cn}, cho-
sen in some way. With this notation the indexing vari-
ables R and C can now express a subset of the data.
Table 1







G1 0 7 8
G2 20 7 8
G3 80 7 8
G4 800 Single dose 8
G5 0 Single dose 2
G6 80 Single dose 2
G7 800 Single dose 2
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A mapping function M is introduced so that M oper-
ates on a real data set (X), mapping the instances in R
and C from X to Z:
Z ¼MðX;R;CÞ or Z ¼MðX;SDÞ
We also deﬁne a consistency function, C, counting
the occurrence of the data mapped in C so that the
indexed variables in C are the ones consistently occur-
ring, i.e., not zeros, more than a fraction, a, counted
over the accompanying object set (R). For completeness,
we also deﬁne the full set (all possible instances of
objects or/and variables) as . This means that a
resulting Z is the subset of objects deﬁned by the set R
(the domain) and the subset of variables deﬁned by C
(the codomain) occurring in subset R more than a frac-
tion a. Formally:
SD ¼ fR;CðÞg
For the selection of a we refer to the discussion. We
also deﬁne an additional operator, V, mapping the
variable space of an SD as
C ¼ VðSDÞ
We also deﬁne a PCA operator, [T, P]=PCA(X,pcs),
performing PCA on the dataset X with the usual output
T (scores) and model P (loadings) using pcs principal
components. The variable V deﬁnes a ﬁnite set of vari-
ances deﬁned by a subset of objects and variables – SD
so that it is expressed as VSD. For simplicity, we also
deﬁne the set of objects (rats) that have not received any
drug as UD (undosed and controls) and the set of objects
that have received the drug (DL-ethionine) as D (dosed).
3.2. Diﬀerential expression analysis
Turning our attention to the variable space, there is a
possible partitioning of occurrences that can be made
since there are at least three possible situations of NMR
peaks occurring:
 Peaks occurring in both the UD and the D part of the
data
 Peaks only occurring in the UD part of the data
 Peaks only occurring in the D part of the data
The peak-aligned data with sparse representation give
us the opportunity to partially diﬀerentiate the peak
origin by searching the data for the sets reﬂecting the
consistent existence of a peak in the UD set. We deﬁne
the endogenous set (ENDO) as:
ENDO ¼ f;VfUD;ð0:75Þgg
representing the full set of objects with the variables
deﬁned as the variables of the UD occurring at least in
75% of the undosed objects. The ENDO peaks are now
the consistently occurring peaks stemming from nor-
mally occurring endogenous metabolites. Note that
these peaks cannot originate from the dosed set, i.e., the
ENDO set is free of the problem of being confounded
with peaks originating from the dosed substance or its
metabolites.
The novel (NOV) partition is now deﬁned as:
NOV0 ¼ f;VðENDOÞg
i.e., the full set of objects but with the variables who
comprise the complement to the variables of the ENDO
set. This subset represents all peaks that are not con-
sistently present in the ENDO set but might be consis-
tent in the D set. To sharpen the set, we check the
consistency of the NOV set with respect to the D set as:
NOV ¼ f;VðD;NOV0ð0:1ÞÞg
consisting only of peaks occurring at and after the onset
of dosing and occurring in more than 10% of the pos-
sible instances in the dosed objects – D. The NOV set
will now deﬁne the relative spectral NMR frequencies
reﬂecting potential biomarkers (BIOM) not present in
the ENDO set and/(or) metabolites originating from the
dosed compound and its metabolites (XENO). The NOV
set will also contain noise, i.e., noise detected as peaks.
Figure 1 depicts the needle vector representation of the
found NOV peaks in the data. Note the distribution of
the NOV peaks (1494 – peaks detected) covering almost
the whole spectral range.
We can now focus our ‘‘bio-pattern’’ or ‘‘metabolic
trace’’ modeling as well as biomarker detection on the
NOV and ENDO sets with less inter-confounding of
the sets.
3.3. Biological noise removal
Turning to the bio-noise artifact, we must redirect the

















Figure 1. NOV peak distribution (spectra from one rat, G4–D1).
Intensity in logarithmic scale for clarity.
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whole NMR data (SD) resulting from a toxicological
metabolic proﬁling study can be partitioned in diﬀerent
ways. One possible way of partitioning is the following:
Variance of SD
¼ variance originating from normally regulating
metabolites ðENDOÞ þ . . . variance originating
from drug administration ðNOVÞ
+...other variance (noise)
or formally
VSD ¼ VENDO þ VNOV þ V"
The ENDO-related variance can again be partitioned into:
VENDO ¼ VBIV þ VBIN
where the biological noise (BIN) variance is primarily
the result of normal biological activity, as explained
in the introduction. This bio-noise reﬂects the variance
in the metabolome stemming from normal (healthy)
time variability and individual diﬀerences and is of
minor interest from a toxicological metabolic proﬁling
perspective; however, this variance blurs the data anal-
ysis by its sheer magnitude. The biologically interesting
variance (BIV) is the portion of variance associated with
distinguishing the toxicity or lesion in the ENDO
expressed by the variables that occur naturally in the rat
metabolome (potential biomarkers or ‘‘bio-patterns’’).
The total variance of the SD can now be expressed by
the sum of the following contributions:
VSD ¼ VBIV þ VBIN þ VNOV þ V"
or as in the Venn diagram in ﬁgure 2.
The goal of the multivariate data analysis is now to
highlight the interesting variables or variable patterns in
the BIV and NOV sets, now without the sets being
obscured by inter-set variance contributions.
The NOV set has already been deﬁned and can safely
be removed from the SD as a set of deﬁned ppm vari-
ables and at the same time we rename the SD to ENDO
since we have partitioned the SD into two new datasets.
In variance terms:
VENDO ¼ VBIV þ VBIN þ V"
The BIN in the data under consideration can be
removed if we can model this fraction of the variance
and then subtract the uninteresting variance from the
data, i.e., ﬁnd a way to make VBIN ﬁ 0.
To express the BIN part (bio-variability/biological
noise) of the data, we must understand that this is a
variable ‘‘pattern’’ describing what is normally expres-
sed in the metabolome of the rat cohort under study. To
express this part of the variance in the ENDO set we
have to express the UD subset as a model and deplete
the ENDO partition of the variance described by this
model.
Now, one naı¨ve way of exhaustively depleting the
ENDO of BIN is to model the UD part of the ENDO
data, i.e., Z ¼MðX;UD;VðENDOÞÞ and
½T;P ¼ PCAðZ; pcsÞ
We now deﬁne XE as XE ¼MðX;;VðENDOÞÞ and
project this set onto the model followed by subtraction,
i.e.,
XBIV ¼ XE  ðXEPÞP0
This projection/subtraction can be viewed as deﬁning
the sub-space of XE in terms of P, reﬂecting the bio-
noise (of the UD set) and collapsing this subspace on the
null-space of XE. This projection/subtraction eﬀectively
cancels the variance in the whole set (XE) that can be
Figure 2. Venn diagram of the data variance partitioning.
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modeled using the UD subset and leaves the new XBIV
matrix depleted of variance related to natural processes
and focused on variability related to non-normal meta-
bolic events, i.e., in this case – the onset of toxicity. We
have coined this set projection/subtraction exhaustive
bio-noise subtraction (EBS). It should also be noted that
if the onset of dosing inﬂicts bionoise with another
variance structure than in the undosed set, this couldnt
be modeled with the EBS. After performing EBS, we
now end up with data (XBIV) expressing the following
variance pattern:
VBIV þ V"
We now have the overall result of being able to par-
tition the data into at least two new sets of interest, the
BIV set, containing the normal metabolite variances
cleaned from biological noise, and the NOV set, con-
taining variances from the biomarkers and the excreted/
metabolized drug. The full data partitioning/projection
can now be summarized by means of a ﬂowchart,
ﬁgure 3.
3.4. Post processing of NMR spectral data
The resulting FT-transformed NMR spectra were
automatically phased, baseline-corrected, and refer-
enced, TSP (d0.0), using in-house software (Phase-
Core–AstraZeneca) written for Matlab (Matlab, 2002).
For the comparison of data processing, the eﬀective
data range was (0.2–10) ppm. The (4.7–4.9) ppm and
(5.7–5.9) ppm spectral regions were excluded from
analysis (water and urea respectively). The spectra were
normalized to constant sum. The ‘‘raw’’ data are the full
(64 k) set down-sampled once, i.e., every other datum
is removed for computational speed. The bucketing was
performed with 0.04 ppm segments with post-summa-
tion of the 2.66 and 2.74 ppm buckets into the 2.70 ppm
and the 2.50 and 2.58 ppm into the 2.54 ppm bucket for
gross correction of the citrate resonances. The bucketing
procedure resulted in a compression from 64 k data/
sample to 205 buckets/sample.
All data analysis was carried out using Matlab. The
algorithm invoked for the PCA analysis was the stan-
dard SVD (Golub and van Loan, 1989) as implemented
in Matlab (T = US, P=V). Peak alignment of the data
was performed using the PARS algorithm with an
in-house software package written for Matlab
(WarpCore–AstraZeneca). The NMR data were
transformed, aligned, and analyzed using the needle-
vector/sparse peak representation, see ﬁgure 4, to a
resolution of 0.001 ppm in the range of (0.2–10) ppm
resulting in 9800 datum/NMR spectrum (3369800 for
the full dataset), which is considered to be the practical
working resolution of the used NMR spectrometer.
All other partitioning, bucketing, wrapping, and
plotting software was developed in-house for Matlab.
All processed partitions are analyzed by PCA using the
covariance matrix, with the exception of the introduc-
tory comparison, which uses the mean of the UD set as
anchor except for the BIV model, which uses the EBS–
PCA model as a multiplicative model of the baseline (the
mean of the UD set is the ﬁrst principal component in
the EBS model).
4. Results
The result is not intended to represent an in-depth
analysis of pathways or lesions but is an attempt to
express the quality and interpretability of the diﬀerently
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Figure 4. NMR data. Inlay depicts the citrate region with the
corresponding sparse/needle vector representation as negative peaks.
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4.1. Pathology of the animal study
DL-ethionine induced the toxicological eﬀects
reported in the literature (Farber, 1967; Glaser and
Mager, 1974). Animals in group 3 lost approximately
10% of their body weight after dosing with 80 mg/kg/
day for 3 days and were euthanised due to ethical rea-
sons (resulting in 140 control and 196 dosed urine
samples for data analysis). In brief, periportal hepatic
steatosis was observed in animals in groups 3, 6, and 7.
In addition, slight liver cell necrosis was also observed in
animals of these groups. Furthermore, all 5 rats from
group 7 showed tubular degeneration in the kidneys and
tubular regeneration was observed in animals treated
with a single high dose of ethionine, necropsied at day 8
(group 4). No other organ toxicities were observed.
4.2. Introductory data comparison by PCA
In order to compare methods, we have separately
analyzed the raw, bucketed, and peak aligned NMR
data. PCA of these three ‘‘native’’ (centered) sets reveals
the following data structure, where relevant score and
loading plots are depicted in ﬁgures 5–13. All three data
sets exhibit a distinct time-/dose-dependent score tra-
jectory expressing the metabolic trace of the drug
impact. Interestingly, there seem to be two phenomena
occurring (tracked by G4) – approximated with one
arrow (from center to G4-D1) as the result of adminis-
tering the drug followed by a transition (G4-D1 to
G4-D4), and a third (G4-D4 to G4-D7), which seem to
express the behavior of the recovery group (G4).
4.3. Diﬀerential expression analysis
From this section on, all models are based on dif-
ferent partitions of aligned data as explained in the post-
processing/theory section.
4.4. The NOV partition
The diﬀerential expression analysis detected 1494
NOV peaks. To ascertain the origin of the NOV peaks
(see ﬁgure 1), we can now model the NOV set with, e.g.,
PCA, or a PARAFAC (Harshman, 1970; Bro, 1997)
model of the matching time resolved part. The results of
the NOV–PCA model can be seen in ﬁgures 14 and 15,
where we can identify two diﬀerent phenomena – one
loading in the same direction as 2.047 ppm (the dosing)
and one related to the 3.278 ppm peak. The peaks
localized between these seem to be involved with the
transition between the two phenomena detected. Note
the few loading variables indicating down regulation –
just as expected.
4.5. The ENDO partition
For completeness a PCA model of the ENDO parti-
tion is depicted in ﬁgures 16 and 17. This is the structure
of the data using only peaks that occur consistently in
the whole UD set, i.e., a PCA model of endogenous































Scores [groups and days]
Figure 5. Scores trace for raw data, PC1 vs. PC2 and PC3 vs. PC2, visualized with small sample statistics. The score ellipses for each group (both
AM and PM samples) are deﬁned by the median (center) and ±MAD (major and minor axes) in score space. Day is indicated by D and group
(last day) by G.























Figure 6. PCs 1 vs. 2 for the raw data, scores on the left pane and loadings on the right. The ﬁfteen largest (Mahalanobis sense) variable loadings



















Figure 7. PCs 3 vs. 2 for the raw data. Loading ppm (2.053, 2.054, 2.052, 2.562, 2.561, 2.561, 2.563, 2.568, 2.567, 2.054, 2.568, 2.052, 2.560, 2.682,


























Scores [groups and days]
Figure 8. Scores trace for bucketed data. Details as in ﬁgure 5.
























Figure 9. PCs 1 vs. 2 for the bucketed data. Asterisks (*) indicate buckets that are confounded with the peaks from the NOV set, see ﬁgure 1.























Figure 10. PCs 3 vs. 2 for the bucketed data. Asterisks (*) indicate buckets that are confounded with the peaks from the NOV set, see ﬁgure 1.





























Scores [groups and days]
Figure 11. Scores trace for aligned data. Details as in ﬁgure 5.
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4.6. Exhaustive bio-noise subtraction (EBS) – the BIV
partition
The diﬀerential expression analysis detected 324
ENDO peaks. A PCA model of the BIV (EBS treated
ENDO set) partition is depicted in ﬁgures 18 and 19.
To validate the BIV set, we also modeled the com-
bined groups G1 (control) and G2 (low dose) that,
according to pathology, did not show any signs of
steatosis, see ﬁgure 20.
In this plot we can clearly see a dose-dependent
behavior of the (low-) dosed animals even though
pathology could not report any toxic lesion indicating
the possibility of an early indication of steatosis.
5. Discussion
5.1. Peak alignment
The conversion from digitized raw spectra to needle
vector representation is straightforward since a peak
integral is (up to a noise factor) proportional to the peak
height. To address the statement that alignment destroys
information about the ion content in the sample
(Cloarec et al., 2005) the following argument may be set
forth: On the contrary, chemometrics is very concerned
about un-confounding. Orthogonality, which is a key
concept in chemometrics, is the opposite to the proposed
modeling of full data. The alignment procedure can be
regarded as a means of un-confounding the data from
shift information. If the shift information found is of
interest, the alignment procedure reports the shift that is
applied to each peak in the spectrum, making it possible
to either append the applied shifts to the data or analyze
these shift data separately. This way of handling and
analyzing the shifts is much more eﬃcient than having
the peaks confounded with the shift phenomena since
the shifts express something diﬀerent than the peak
intensities. It should be emphasized that all relative
NMR frequency values reported for the aligned data are
at the resolution R=0.001 ppm as opposed to the buc-






























Figure 13. PCs 3 vs. 2 for the aligned data. Hashes (#) indicate loadings that are common with the bucket model. Loading ppm (3.278, 2.047#,






























Figure 12. PCs 1 vs. 2 for the aligned data. Hashes (#) indicate loadings that are common with the bucket model. Loading ppm (2.047#, 2.564,
2.685#, 3.013#, 2.537#, 2.446#, 2.712#, 3.278, 1.314#, 4.647, 4.660, 3.001#, 3.488#, 2.457#, 2.434#). Other details as in ﬁgure 6.
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that the peak-tracking algorithm used is set to trace the
most prominent peaks. A more realistic peak count for
this data is approx. 5–6000 peaks/sample (results not
shown).
5.2. Introductory comparison of the data by PCA
As can be seen we do not report any cross-validation
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Figure 15. PCs 1 vs. 2 for the NOV data. Loading ppm (2.047, 3.278, 3.040, 1.314, 2.052, 3.291, 4.647, 2.037, 1.327, 1.309, 1.340, 3.934, 3.488,
3.447, 3.033). Other details as in ﬁgure 6.
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in this case since we only are interested in biomarker
detection, i.e., a covariance map of the data in question.
It is also dangerous to use the (blocked) CV when there
are comparably few samples spanning the interesting
metabolic trajectory, i.e., the chance of an important
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Figure 17. PCs 1 vs. 2 for the ENDO data. Loading ppm. (3.269, 2.564, 2.685, 2.537, 3.013, 2.446, 2.712, 3.001, 2.457, 1.304, 4.660, 2.434, 3.024,
3.414, 3.047). Other details as in ﬁgure 6.
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from a uniform distribution. In addition, the ﬁnal
models are not used for prediction, making the CV
analysis uninformative.
The conclusion of the introductory comparison is
that the three diﬀerent methods result in a time-/dose-
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Figure 19. PCs 1 vs. 2 for the BIV set. Loading ppm (1.326, 1.304, 1.332, 4.660, 1.345, 1.291, 2.063, 3.502, 5.249, 3.890, 5.243, 2.610, 3.547, 3.461,
1.218). Other details as in ﬁgure 6.
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model that (as expected) mostly reﬂects the shifting of
the citrate peaks. In the bucketed model, although dis-
playing a nice trajectory, the indicated important load-
ing variables are ‘‘contaminated’’ with peaks originating
from the NOV partition, calling into question the
validity of the indicated peaks. As for the aligned data,
the model reﬂects approximately the same variance
pattern and important relative NMR frequencies as the
bucketed model, indicating a successful alignment.
5.3. Diﬀerential expression analysis – selection of 
The only user-deﬁned parameter in the diﬀerential
expression analysis is the peak consistency parameter
alpha. Given that we want to detect the ENDO partition
with some consistency and given that the alignment
procedure can fail for some peaks, a value of 75% is
reasonable and suﬃcient (lower bound). For the
‘‘cleanup’’ of the NOV partition, some prior knowledge
of half-life of the dosed compound is beneﬁcial. Assum-
ing an approximate half-life of 12 h, we should be able to
track the compound for at least 2 days, making the
window of detection at least 4 samples out of 16 possible
(25%). In view of this a threshold of 10% is reasonable.
The selection is not crucial if the choices are made to
incorporate more peaks. The subsequent data analysis
(PCA) and additional conﬁrmation in the raw spectra
will eﬀectively screen out any spurious NMR variables.
5.4. The NOV partition
The fact that the NOV peaks are in abundance and
distributed over the whole spectral range in this case
questions the use of the bucketing tactic since removal/
deletion or replacement (Ebbels et al., 2002) of all the
aﬀected buckets would result in virtually no data left to
model. In other words, the probability that any bucket
segment will be confounded with at least one NOV peak
is high. In this study 95% (1494 NOV peaks indicated)
of the buckets are confounded with peaks from the NOV
set, leaving only 11 buckets un-confounded. This makes
the PCA analysis of bucketed data self-validating since
it is diﬃcult a priori to remove all peaks originating from
the administered drug or its metabolites or any other
peaks co-varying with the administration of the dosed
compound that are not biomarkers.
Even though the NOV set holds out the promise of
detecting ‘‘biomarkers’’ (as new peaks, correlating with
the pathology), we have not further elucidated the par-
titioning (BIOM/XENO) and modeling of the NOV set
in this paper since it ultimately requires detection and
deletion of the administered compound and its metab-
olite peaks from the NOV data. It should be stated that
this deletion/partitioning step is now a much simpler
process since the NOV set has been deﬁned/extracted,
thereby becoming open to biomarker detection less
aﬀected by other variances. The PCA model of the NOV
set also reveals a clustering in loading directions, indi-
cating groups of peaks with diﬀerent pharmacokinetics,
which is a very useful phenomenon when it comes to
ascertaining the peak origin. There is now also the
possibility of modeling the NOV data with PARAFAC
or Tucker types of models since parts of the data (G1,
G2 & G4) can be ordered in a tensor with time as one
dimension (rattimeNMR) enabling resolution of
time dependent phenomena, possibly revealing the
pharmacokinetics of the diﬀerent events (Connor et al.,
2004; Dyrby et al., 2005). In this case any clustering or
relevant time-trajectory of the NOV partition indicates
loadings with peaks related to either the XENO or the
BIOM set of peaks, opening up the way for further
model-based assignment of peaks into the XENO or
BIOM set.
The power of the PCA–NOV model can be visualized
by plotting some indicated spectral areas over time,
ﬁgures 21 and 22, and by plotting the mean value of the
spectral peaks over time, ﬁgure 23. The plots reveal






















Figure 20. PCs 1 vs. 2 for the BIV set of groups G1 and G2. Undosed (Æ), Dosed(+). Loading ppm (1.304, 1.313, 1.326, 3.803, 3.928, 3.867,
3.651, 3.831, 2.039, 1.986, 3.414, 3.427, 3.977, 3.656, 3.257). Other details as in ﬁgure 6.
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5.5. Biological noise removal (EBS) and the BIV
partition
When comparing the models of the ENDO and the
BIV sets, it is obvious that the impact of the peaks has
changed. EBS eﬀectively reweighs the variables to reﬂect
variance patterns not easily detected in the UD set,
putting emphasis on the changes occurring as a conse-
quence of the transition between UD and D, i.e., we get
an immediate focus on the variables exhibiting a vari-
ance pattern that cannot be accounted for as being
‘‘normal’’ variation.
One issue with EBS is the number of PCs to use for
this projection/subtraction. From a data-modeling point
of view, we would like all the biological noise to be
canceled, which calls for a relatively high number of
PCs; in addition, the variance in the UD subset of the
data cannot be of interest for the subsequent data
analysis if the toxic event is the focus of the analysis. In
other words, there can be no variance of interest from a
toxicological perspective in the control set. If there is
any variance related to latent biological noise in the data
part reﬂecting the dosing (D), this portion of variance
can safely be removed since it is based on the natural
bio-variability of the studied rats. This makes the choice
of model dimensionality straightforward: one must at
least extract as many PCs as there are latent phenomena
in the UD set. If one extracts too many, this is of minor
concern since the ‘‘loading patterns’’ associated with
these PCs will not be present (in large magnitude) in the
full data, i.e., these loadings will model bio-noise at an
individual rat level, eﬀectively screening out ‘‘outlying’’
individual rats. Hence the overall data will not be
aﬀected by the choice of model dimensionality as long as
the number is not too small. For this work we have
chosen pcs=9, which might be considered a large
number; however since there are (752)2=140 urine
spectra in the UD set expressing partially unique bio-
variability patterns, the ﬁgure is reasonable. The sensi-
tivity of the choice of PCs can be made clear by, for
instance, plotting the explained variance (as sums of
squares) for diﬀerent choices of PCs, see ﬁgure 24.
The plot reveals a smooth asymptotic behavior of the
modeling power of each PC, indicating that later PCs
are explaining noise or individual rats. The ﬁgure also
shows that approximately 70% of the variance of the
ENDO set can be traced to the bio-variability expressed
by the UD partition, leaving 30% of the variance
explaining changes in the metabolome that cannot be
accounted for by the natural variability.
The spectral areas indicated by four selected loading
variables from the BIV model, ﬁgure 19, are depicted in
ﬁgures 25 and 26.
To further visualize the ﬁndings in the BIV set, we can
plot the time trajectory for the same peaks, see ﬁgure 27.
The ﬁndings for the indicated BIV–G1G2 model can
be further validated by analyzing the mean intensities for
the full time evolution of some of the peaks of interest for
all rats and all groups in the study, see ﬁgure 28.
It is also noteworthy how the EBS correction brings
the distinct ‘‘triangular’’ metabolic trajectory back from
the processed ENDO set. It is clear that the ENDO set is
heavily ‘‘contaminated’’ with large variances originating
from the normally regulating rat metabolome, whereas
the BIV set again exhibits the dose trajectory similar to
the one seen in the un-processed data, compare ﬁg-
ures 16–17 with 18–19. In this study the EBS has been
used in a naı¨ve way. A more powerful way of performing
EBS is to build a ‘‘database’’ of control and pair-fed
animals, making the EBS correction a global correction.
Another interesting feature of the EBS projection is that
it can be performed on three- or higher way tensors (e.g.,
MS/MS or LC/MS data) by using high-order decom-
position methods such as Tucker or PARAFAC with, in
essence, the same philosophical approach.
6. Concluding remarks
In this paper we indicate methods for circumventing
what has been addressed as problems in the multivariate
Figure 22. Timeplot of segments/peaks indicated by the NOV model,
see ﬁgure 15. Left segment center 3.040 ppm, right segment center
1.314 ppm. Other details as in ﬁgure 21.
Figure 21. Timeplot of spectral segments (width=0.04 ppm) of peaks
indicated by the NOV model, see ﬁgure 15. Left segment center
2.047 ppm, right segment center 3.278 ppm. Upper half is dosed (G4),
lower half is control animal (G1). Time points from bottom up in each
half ()5, )2, 1, 2, 3, 4, 5, 6, 7), )5 and )2 one sample/day, 1–7 two
samples/day.
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analysis of NMR data in a metabolic proﬁling con-
text namely unaligned peaks, biological noise, detec-
tion of consistent peaks, and the segment integration
issue.
We indicate that diﬀerential expression analysis of
peak aligned NMR data in the context of metabolic
proﬁling is possible. We show that, with proper under-
standing of the confounding factors, these factors can be
removed and/or diﬀerentiated into diﬀerent data sets
and the processed data can be further analyzed, reveal-
ing the metabolites reﬂecting the biological system under
study. This analysis can, furthermore, be done using
unsupervised methods resulting in unbiased modeling.
We have also shown that it is possible to remove vari-
ance related to normal bio-variability from parts of the
data.








































Figure 24. Left pane: explained variance of the EBS correction of the ENDO set, left bars= UD, right bars=UD+D(X). Right pane: delta
explained variance between PCs. Horizontal line in right pane is at 1/140 – the expected variance contribution of one sample with random
variables.
G1 G2 G3 G4 G5 G6 G7
2.047 [ppm]
G1 G2 G3 G4 G5 G6 G7
3.278 [ppm]
G1 G2 G3 G4 G5 G6 G7
3.040 [ppm]
G1 G2 G3 G4 G5 G6 G7
1.314 [ppm]
Figure 23. Barplots of the four largest variances indicated by the NOV model, see ﬁgure 15. The mean of the intensity for the respective relative
NMR frequency for all the rats in a group is pooled into one bar. Time points from left to right ()5, )2, 1, 2, 3, 4, 5, 6, 7) for all groups (G1–7).
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Furthermore, the proposed analysis scheme is
made with the practical instrument resolution, facil-
itating the search for indicative chemical shifts and
hereby also the assignment of peaks (chemical
structure) reﬂecting the changes in the metabolome.
The indicated possibility of ﬁnding relevant NMR
peaks at this resolution opens up interesting possi-
bilities.
We have shown that the information revealed by the
PCA models of the diﬀerent data partitions diﬀers
from the models of bucketed or raw-data. The models
of raw data are complex due to the included modeling
of shifting peaks and peak shape diﬀerences. We have
also shown that models of ‘‘bucketed’’ data are aﬀected
by a multitude of peaks/variances that cannot be
accounted for by the normally regulating metabolome
or adjusted for by simply removing/replacing a few
‘‘buckets.’’
The PARS alignment and the needle/sparse vector
representation combined with diﬀerential expression
analysis and the further partitioning combined with
exhaustive bionoise subtraction (EBS) constitutes a
straightforward data-processing scheme which unlocks
more information at a resolution not hitherto
achieved.
Figure 25. Timeplot of segments/peaks indicated by the BIV model,
see ﬁgure 19. Left segment center 1.304 ppm, right segment center
3.502 ppm. Lower half is control animal (10) (G1), other details as in
ﬁgure 21.
Figure 26. Timeplot of segments/peaks indicated by the BIV model,
see ﬁgure 19. Left segment center 4.660 ppm, right segment center
5.243 ppm. Lower half is control animal (10) (G1), other details as in
ﬁgure 21.
G1 G2 G3 G4 G5 G6 G7
1.304 [ppm]
G1 G2 G3 G4 G5 G6 G7
4.660 [ppm]
G1 G2 G3 G4 G5 G6 G7
3.502 [ppm]
G1 G2 G3 G4 G5 G6 G7
5.243 [ppm]
Figure 27. Barplots of BIV model, see ﬁgure 19. Details as in ﬁgure 23.
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